Prof. PeptideProf. Peptide

Epitalon vs NAD+ — Trial Data and Molecule Identity

Epitalon and NAD+ (raised via NMN or NR) are both discussed in longevity research, but the evidence bases are not comparable in the way they are sometimes presented. This page separates Epitalon's own trial data from a Russian cohort study that is often cited for it but tested a different compound, and reports the NAD+ precursor trial data alongside it — each figure attributed to its source.

On this page
  1. 1.Mechanism
  2. 2.Epitalon vs Epithalamin/Thymalin — Not the Same Evidence Base
  3. 3.Human Evidence, by Compound
  4. 4.Evidence Level
  5. 5.FAQ
  6. 6.References

Mechanism

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly). Its most-cited mechanism is telomerase activation — cell-culture work reports it binds ATTTC sequences in the promoter region of the telomerase gene and upregulates hTERT expression (Khavinson et al. 2003, PMID 12937682; an unaffiliated group reported a similar result in breast-cancer and normal cell lines, Al-Dulaimi et al. 2025, PMID 40908429, with a published correction, PMID 41240216). It is also studied for restoration of pineal melatonin secretion and circadian gene expression.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, required by sirtuin enzymes (which regulate cellular aging programs), PARP enzymes (DNA repair), and mitochondrial energy metabolism. NAD+ is too large to supplement directly; it is raised via smaller precursor molecules — principally NMN and NR — that the body converts into NAD+.

Epitalon vs Epithalamin/Thymalin — Not the Same Evidence Base

Epitalon is a synthetic tetrapeptide developed as a short-peptide analog of epithalamin, a natural pineal-gland extract studied by Khavinson and colleagues in Soviet-era gerontology research. They are related but distinct preparations.

The multi-decade Russian human mortality-reduction cohort research most often cited for Epitalon — Khavinson & Morozov 2003 (PMID 14523363), which followed 266 elderly subjects for 6–8 years and reported a reduced mortality rate — treated Thymalin (a thymic peptide preparation) and Epithalamin (the natural pineal extract). The paper's own text does not name Epitalon and does not test the synthetic AEDG peptide. That cohort's mortality data does not carry over to Epitalon.

Epitalon's own identified evidence is narrower: a rat reproductive-aging model (Arutjunyan et al. 2012, PMID 23237594, which tested both epithalamine and epitalon) and one short human ocular trial (Khavinson et al. 2002, PMID 12195242, retinitis pigmentosa via parabulbar injection). See the Epitalon profile for the full treatment of this distinction.

Human Evidence, by Compound

EpitalonNAD+ (via NMN/NR)
Compound typeSynthetic tetrapeptide (Ala-Glu-Asp-Gly)Coenzyme — raised via precursors NMN or NR, not supplemented directly
Primary mechanismReported telomerase (hTERT) activation and pineal/melatonin restorationSubstrate for sirtuin and PARP enzymes; mitochondrial energy metabolism
Strongest human evidenceOne short ocular trial (Khavinson et al. 2002, PMID 12195242) — retinitis pigmentosa, parabulbar injectionRandomized double-blind trials: NMN (Yoshino et al. 2021, PMID 33888596) and NR (Martens et al. 2018, PMID 29599478)
Multi-decade Russian cohort dataDoes NOT apply — that cohort (Khavinson & Morozov 2003, PMID 14523363) treated Thymalin and Epithalamin, natural gland extracts, not synthetic EpitalonNot applicable — NAD+ precursor trials are separate, shorter-duration studies
Animal evidenceRat reproductive-aging model (Arutjunyan et al. 2012, PMID 23237594)Extensive rodent NAD+-restoration literature; not the focus of this comparison
Regulatory statusNot FDA-approved — sold as a research peptideNMN and NR sold as dietary supplements in the US; not FDA-approved as drugs

Yoshino et al. 2021 (Science, PMID 33888596) randomized postmenopausal women with prediabetes who were overweight or obese to 10 weeks of NMN or placebo, double-blind. Insulin-stimulated glucose disposal (measured by hyperinsulinemic-euglycemic clamp) and skeletal-muscle insulin signaling increased with NMN and did not change with placebo.

Martens et al. 2018 (Nat Commun, PMID 29599478) is a randomized, double-blind, placebo-controlled crossover trial (2 × 6 weeks) of NR in healthy middle-aged and older adults, reporting the supplement was well tolerated and effectively raised NAD+ metabolism.

Christen et al. 2026 (Nat Metab, PMID 41540253) directly compared NR, NMN, and nicotinamide in 65 healthy participants over 14 days — randomized and placebo-controlled, but open-label, not double-blind. NR and NMN comparably raised circulating NAD+; nicotinamide did not produce the same sustained effect. No equivalent human trial — head-to-head or otherwise beyond the single ocular study above — exists for Epitalon.

Evidence Level

Epitalon: Animal Model (Arutjunyan et al. 2012, PMID 23237594) for the reproductive-aging/circadian mechanism; Human Observational for the retinitis-pigmentosa ocular trial (Khavinson et al. 2002, PMID 12195242) — a single short trial in a specific eye condition and route, not systemic or longevity-relevant human data. NMN: Human RCT (Yoshino et al. 2021, PMID 33888596). NR: Human RCT (Martens et al. 2018, PMID 29599478). The three-way head-to-head (Christen et al. 2026, PMID 41540253) is Human RCT but open-label, not double-blind.

FAQ

Is the Khavinson mortality-reduction cohort evidence for Epitalon?

No. Khavinson & Morozov 2003 (PMID 14523363) followed 266 elderly subjects for 6–8 years and reported reduced mortality with Thymalin (a thymic peptide preparation) and Epithalamin (a natural pineal-gland extract). Neither preparation is the synthetic AEDG tetrapeptide sold as Epitalon. The paper's own text names Thymalin and Epithalamin throughout and does not use the name Epitalon.

What is Epitalon's own human evidence?

One identified short trial: Khavinson et al. 2002 (PMID 12195242) reports Epitalon treatment for retinitis pigmentosa via parabulbar (near-the-eye) injection, finding a positive clinical effect in 90% of cases. The paper's own abstract does not state a patient count, control-group design, or specific effect sizes. A 2025 review (Araj et al., Int J Mol Sci, PMC11943447) summarizes those specifics — 162 patients aged 18–72, 5.0 µg of Epitalon per eye for 10 consecutive days against a conventionally-treated control group — but those numbers are sourced to the review's summary, not independently confirmed in the primary paper's own text.

Do NMN and NR have randomized controlled trials in humans?

Yes. Yoshino et al. 2021 (Science, PMID 33888596) is a 10-week, randomized, double-blind, placebo-controlled trial of NMN in postmenopausal women with prediabetes, reporting increased insulin-stimulated glucose disposal and skeletal-muscle insulin signaling versus placebo. Martens et al. 2018 (Nat Commun, PMID 29599478) is a randomized, double-blind, placebo-controlled crossover trial of NR in healthy middle-aged and older adults, reporting NAD+ metabolome changes and good tolerability.

Is there a trial comparing NMN and NR directly?

Yes. Christen et al. 2026 (Nat Metab, PMID 41540253) is a randomized, open-label, placebo-controlled trial in 65 healthy participants (not double-blind) comparing 14 days of NR, NMN, and nicotinamide (Nam). NR and NMN comparably increased circulating NAD+; Nam did not produce the same sustained increase. No equivalent head-to-head trial exists for Epitalon against any other longevity compound.

References

  1. Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-8. https://pubmed.ncbi.nlm.nih.gov/12195242/
  2. Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-40. https://pubmed.ncbi.nlm.nih.gov/14523363/
  3. Arutjunyan A, Kozina L, Milyutina Y, Korenevsky A, Stepanov M, Arutyunov V. Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats. Curr Aging Sci. 2012;5(3):178-85. https://pubmed.ncbi.nlm.nih.gov/23237594/
  4. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-2. https://pubmed.ncbi.nlm.nih.gov/12937682/
  5. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. Correction published: Biogerontology. 2025;27(1):1, PMID 41240216 (Figs. 1–3 replaced). https://pubmed.ncbi.nlm.nih.gov/40908429/
  6. Araj SK, Brzezik J, et al. Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/
  7. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. https://pubmed.ncbi.nlm.nih.gov/33888596/
  8. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. https://pubmed.ncbi.nlm.nih.gov/29599478/
  9. Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026;8(1):62-73. https://pubmed.ncbi.nlm.nih.gov/41540253/
Epitalon ProfileNAD+ ProfileNMN ProfileNAD+ Dosing Guide

Have a question about Epitalon vs NAD+ — Trial Data and Molecule Identity? Send us an email